1. Home
  2. Stocks
  3. Lauruslabs Share Price
  • Chart
  • F&O
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • Similar Stocks
  • FAQs

    • Laurus Labs Share Price

    Large Cap
    ₹454.5
    + 15.25 (3.47%)
    • Advice
    • Hold
    09 October, 2024 12:39 BSE: 540222 NSE: LAURUSLABS ISIN: INE947Q01028
    Split

    Start SIP in Laurus Labs

    Start SIP

    Laurus Labs Performance

    Day Range

    • Low 441
    • High 456
    ₹ 454

    52 Week Range

    • Low 349
    • High 518
    ₹ 454
    • Open Price442
    • Previous Close439
    • Volume1191760

    Laurus Labs Chart

    • Over 1 Month -6.2%
    • Over 3 Month -4.84%
    • Over 6 Month -2.37%
    • Over 1 Year + 13.31%

    Laurus Labs Key Statistics

    P/E Ratio 165.3
    PEG Ratio -2.2
    Market Cap Cr 24,505
    Price to Book Ratio 6
    EPS 4.2
    Dividend 0.2
    Relative Strength Index 36.49
    Money Flow Index 30.52
    MACD Signal -0.62
    Average True Range 14.44

    Laurus Labs F&O

    Laurus Labs Futures Laurus Labs Option Chain

    Laurus Labs Investment Rating

    • Master Rating:

    • Laurus Labs has an operating revenue of Rs. 5,053.95 Cr. on a trailing 12-month basis. An annual revenue de-growth of -16% needs improvement, Pre-tax margin of 5% is okay, ROE of 3% is fair but needs improvement. The company has a reasonable debt to equity of 19%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -9% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 22 which is a POOR score indicating inconsistency in earnings, a RS Rating of 29 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 46 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Laurus Labs Financials
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 1,1171,4151,1321,1581,1081,279
    Operating Expenses Qtr Cr 9561,1439629789801,027
    Operating Profit Qtr Cr 161271170181128252
    Depreciation Qtr Cr 918987858481
    Interest Qtr Cr 414238383341
    Tax Qtr Cr 10431417435
    Net Profit Qtr Cr 29121434713102
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 4,8605,789
    Operating Expenses Annual Cr 4,0634,292
    Operating Profit Annual in Cr 7501,482
    Depreciation Cr 345301
    Interest Annual Cr 151146
    Tax Annual Cr 78291
    Net Profit Annual Cr 224760
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 659882
    Cash from Investing Activity Annual Cr -757-735
    Cash from Financing Annual Activity Cr 139-185
    Net Cash Flow Annual Cr 41-39
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 4,2074,057
    Fixed Assets Annual Cr 3,1923,241
    Total Non Current Assets Annual Cr 4,1503,787
    Total Current Assets Annual Cr 3,5173,171
    Total Assets Annual Cr 7,6676,958
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 7875
    ROE Annual % 519
    ROCE Annual % 925
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1726
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 1,1951,4401,1951,2241,1821,381
    Operating Expenses Qtr Cr 1,0241,1981,0141,0371,0151,095
    Operating Profit Qtr Cr 171241181188167286
    Depreciation Qtr Cr 10610298939187
    Interest Qtr Cr 495151423953
    Tax Qtr Cr 6329151240
    Net Profit Qtr Cr 1376233725103
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 5,0676,047
    Operating Expenses Annual Cr 4,2634,448
    Operating Profit Annual in Cr 7781,592
    Depreciation Cr 385324
    Interest Annual Cr 183165
    Tax Annual Cr 68312
    Net Profit Annual Cr 161790
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 666994
    Cash from Investing Activity Annual Cr -822-996
    Cash from Financing Annual Activity Cr 250-27
    Net Cash Flow Annual Cr 93-29
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 4,1114,038
    Fixed Assets Annual Cr 4,0673,713
    Total Non Current Assets Annual Cr 4,5524,199
    Total Current Assets Annual Cr 3,8353,462
    Total Assets Annual Cr 8,3877,660
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 7675
    ROE Annual % 420
    ROCE Annual % 824
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1626
    Invest in Laurus Labs

    Laurus Labs Technicals

    EMA & SMA

    Current Price
    ₹454.5
    + 15.25 (3.47%)
    pointer
    • Bullish Moving Average
    • ___
    • 6
    • Bearish Moving Average
    • ___
    • 10
    • 20 Day
    • ₹463.04
    • 50 Day
    • ₹461.38
    • 100 Day
    • ₹451.67
    • 200 Day
    • ₹435.57
    • 20 Day
    • ₹474.94
    • 50 Day
    • ₹459.76
    • 100 Day
    • ₹450.84
    • 200 Day
    • ₹432.64

    Laurus Labs Resistance and Support

    PIVOT
    ₹436.8
    Resistance
    First Resistance 444.45
    Second Resistance 449.65
    Third Resistance 457.30
    RSI 36.49
    MFI 30.52
    MACD Single Line -0.62
    MACD -6.45
    Support
    First Support 431.60
    Second Support 423.95
    Third Supoort 418.75

    Laurus Labs Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 808,834 34,335,003 42.45
    Week 1,604,126 66,442,889 41.42
    1 Month 2,284,824 86,023,642 37.65
    6 Month 2,355,194 98,753,285 41.93

    Laurus Labs Result Highlights

    Laurus Labs Synopsis

    NSE-Medical-Diversified

    Laurus Labs is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company’s Total Operating Revenue is Rs. 4812.39 Cr. and Equity Capital is Rs. 107.79 Cr. for the Year ended 31/03/2024. Laurus Labs Ltd. is a Public Limited Listed company incorporated on 19/09/2005 and has its registered office in the State of Andhra Pradesh, India. Company’s Corporate Identification Number(CIN) is L24239AP2005PLC047518 and registration number is 047518.
    Market Cap 23,683
    Sales 4,822
    Shares in Float 39.36
    No of funds 224
    Yield 0.18
    Book Value 5.63
    U/D Vol ratio 1.5
    LTDebt / Equity 12
    Alpha -0.07
    Beta 1.06

    Laurus Labs Shareholding Pattern

    Owner NameJun-24Mar-24Dec-23Sep-23
    Promoters 27.18%27.19%27.19%27.2%
    Mutual Funds 9.18%6.68%5.58%5.29%
    Insurance Companies 3.94%4.75%5.19%5.41%
    Foreign Portfolio Investors 25.67%25.98%25.39%24.03%
    Financial Institutions/ Banks 0.01%0.01%
    Individual Investors 22.68%23.95%25.02%26.49%
    Others 11.35%11.45%11.62%11.57%

    Laurus Labs Management

    Name Designation
    Dr. Ravindranath Kancherla Non Exe.Chairman&Ind.Director
    Mr. V V Ravi Kumar Executive Director & CFO
    Dr. Satyanarayana Chava Executive Director & CEO
    Dr. C V Lakshmana Rao Executive Director
    Mr. Krishna Chaitanya Chava Executive Director
    Ms. Soumya Chava Executive Director
    Dr. Rajesh Koshy Chandy Independent Director
    Mrs. Aruna Rajendra Bhinge Independent Director
    Mr. Karnam Sekar Independent Director

    Laurus Labs Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Laurus Labs Corporate Action

    Date Purpose Remarks
    2024-07-25 Quarterly Results
    2024-04-25 Audited Results & Interim Dividend
    2024-01-24 Quarterly Results
    2023-10-20 Quarterly Results & Interim Dividend
    2023-07-27 Quarterly Results
    Date Purpose Remarks
    2024-05-08 INTERIM Rs.0.40 per share(20%)Interim Dividend
    2023-11-02 INTERIM Rs.0.40 per share(20%)Interim Dividend
    2023-05-10 INTERIM Rs.1.20 per share(60%)Interim Dividend
    2022-11-04 INTERIM Rs.0.80 per share(40%)Interim Dividend
    2022-05-11 INTERIM Rs.1.20 per share (60%) Second Interim Dividend
    Date Purpose Remarks
    2020-09-30 Split Rs.0.00 split from Rs. 10/- to Rs. 2/-.

    Laurus Labs FAQs

    What is Share Price of Laurus Labs ?

    Laurus Labs share price is ₹454 As on 09 October, 2024 | 12:25

    What is the Market Cap of Laurus Labs ?

    The Market Cap of Laurus Labs is ₹24504.8 Cr As on 09 October, 2024 | 12:25

    What is the P/E ratio of Laurus Labs ?

    The P/E ratio of Laurus Labs is 165.3 As on 09 October, 2024 | 12:25

    What is the PB ratio of Laurus Labs ?

    The PB ratio of Laurus Labs is 6 As on 09 October, 2024 | 12:25

    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     
    footer_form

    Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

    Q2FY23

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of ₹10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.